Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

BMC Immunology

Volumn 10, Issue , 2009, Pages

  Vora, Kalpit A ^a   Porter, Gene ^a   Peng, Roche ^a   Cui, Yan ^a   Pryor, Kellyann ^a   Eiermann, George ^a   Zaller, Dennis M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 2; MINOR HISTOCOMPATIBILITY ANTIGEN; OVALBUMIN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME INHIBITION; FEMALE; GERMINAL CENTER; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHADENOPATHY; LYMPHATIC DRAINAGE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; WILD TYPE; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MALE; MOUSE MUTANT; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD26; FEMALE; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES;

EID: 65149091474     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-10-19     Document Type: Article

References (55)

1. Gorrell MD Gysbers V McCaughan GW CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes Scand J Immunol 2001, 54:249-64 10.1046/j.1365-3083.2001.00984.x 11555388
2. Drucker DJ Nauck MA The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006, 368:1696-705 10.1016/S0140-6736(06)69705-5 17098089
3. Green BD Flatt PR Bailey CJ Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes Expert Opin Emerg Drugs 2006, 11:525-39 10.1517/14728214.11.3.525 16939389
4. Nathan DM Buse JB Davidson MB Ferrannini E Holman RR Sherwin R Zinman B Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy Diabetes Care 2009, 32:193-203 10.2337/dc08-9025 18945920
5. Richter B Bandeira-Echtler E Bergerhoff K Lerch CL Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2008:CD006739 18425967
6. Williams-Herman D Round E Swern AS Musser B Davies MJ Stein PP Kaufman KD Amatruda JM Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis BMC Endocr Disord 2008, 8:14 2605739 18954434 10.1186/1472-6823-8-14
7. Aytac U Dang NH CD26/dipeptidyl peptidase IV: A regulator of immune function and a potential molecular target for therapy Curr Drug Targets Immune Endocr Metabol Disord 2004, 4:11-8 10.2174/1568008043340035 15032621
8. Coburn MC Hixson DC Reichner JS In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV Cell Immunol 1994, 158:269-80 10.1006/cimm.1994.1275 7923383
9. Narducci MG Scala E Bresin A Caprini E Picchio MC Remotti D Ragone G Nasorri F Frontani M Arcelli D et al Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/ dipeptidylpeptidase IV Blood 2006, 107:1108-15 10.1182/ blood-2005-04-1492 16204308
10. Yan S Marguet D Dobers J Reutter W Fan H Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen Eur J Immunol 2003, 33:1519-27 10.1002/eji.200323469 12778469
11. Kruschinski C Skripuletz T Bedoui S Tschernig T Pabst R Nassenstein C Braun A von Horsten S CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model Clin Exp Immunol 2005, 139:17-24 1809259 15606609 10.1111/j.1365-2249.2005.02666.x
12. Bristol LA Sakaguchi K Appella E Doyle D Takacs L Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26 J Immunol 1992, 149:367-72 1352525
13. Martin M Huguet J Centelles JJ Franco R Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule J Immunol 1995, 155:4630-43 7594462
14. Munoz E Blazquez MV Madueno JA Rubio G Pena J CD26 induces T-cell proliferation by tyrosine protein phosphorylation Immunology 1992, 77:43-50 1421601 1356916
15. Lankas GR Leiting B Roy RS Eiermann GJ Beconi MG Biftu T Chan CC Edmondson S Feeney WP He H et al Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 2005, 54:2988-94 10.2337/ diabetes.54.10.2988 16186403
16. Bank U Heimburg A Helmuth M Stefin S Lendeckel U Reinhold D Faust J Fuchs P Sens B Neubert K et al Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) - a novel approach for the treatment of inflammatory bowel disease Int Immunopharmacol 2006, 6:1925-34 10.1016/ j.intimp.2006.09.014 17161345
17. Flentke GR Munoz E Huber BT Plaut AG Kettner CA Bachovchin WW Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function Proc Natl Acad Sci USA 1991, 88:1556-9 51058 1671716 10.1073/ pnas.88.4.1556
18. Korom S De Meester I Schmidbauer G Pratschke J Brendel MD Durinx C Schwemmle K Haemers A Scharpe S Kupiec-Weglinski JW Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: Effects on humoral immunity Transplant Proc 1999, 31:778 10.1016/ S0041-1345(98)02069-7 10083329
19. Reinhold D Bank U Buhling F Tager M Born I Faust J Neubert K Ansorge S Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes Immunol Lett 1997, 58:29-35 10.1016/ S0165-2478(97)02716-8 9436466
20. Schon E Jahn S Kiessig ST Demuth HU Neubert K Barth A Von Baehr R Ansorge S The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro Eur J Immunol 1987, 17:1821-6 10.1002/eji.1830171222 2891539
21. Steinbrecher A Reinhold D Quigley L Gado A Tresser N Izikson L Born I Faust J Neubert K Martin R et al Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo J Immunol 2001, 166:2041-8 11160254
22. Conarello SL Li Z Ronan J Roy RS Zhu L Jiang G Liu F Woods J Zycband E Moller DE et al Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc Natl Acad Sci USA 2003, 100:6825-30 164531 12748388 10.1073/pnas.0631828100
23. Marguet D Baggio L Kobayashi T Bernard AM Pierres M Nielsen PF Ribel U Watanabe T Drucker DJ Wagtmann N Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc Natl Acad Sci USA 2000, 97:6874-9 18768 10823914 10.1073/pnas.120069197
24. Mu J Woods J Zhou YP Roy RS Li Z Zycband E Feng Y Zhu L Li C Howard AD et al Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic {beta}-Cell Mass and Function in a Rodent Model of Type 2 Diabetes Diabetes 2006, 55:1695-704 10.2337/db05-1602 16731832
25. Jacob J Kassir R Kelsoe G In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations J Exp Med 1991, 173:1165-75 2118845 1902502 10.1084/jem.173.5.1165
26. Vora KA Wang LC Rao SP Liu ZY Majeau GR Cutler AH Hochman PS Scott ML Kalled SL Cutting edge: Germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function J Immunol 2003, 171:547-51 12847217
27. Vora KA Ravetch JV Manser T Amplified follicular immune complex deposition in mice lacking the Fc receptor gamma-chain does not alter maturation of the B cell response J Immunol 1997, 159:2116-24 9278297
28. Vora KA Tumas-Brundage KM Manser T A periarteriolar lymphoid sheath-associated B cell focus response is not observed during the development of the anti-arsonate germinal center reaction J Immunol 1998, 160:728-33 9551908
29. Wang W Golding B The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets Immunol Lett 2005, 100:195-201 10.1016/j.imlet.2005.04.003 15916814
30. Preller V Gerber A Wrenger S Togni M Marguet D Tadje J Lendeckel U Rocken C Faust J Neubert K et al TGF-beta1-Mediated Control of Central Nervous System Inflammation and Autoimmunity through the Inhibitory Receptor CD26 J Immunol 2007, 178:4632-40 17372022
31. Kelsoe G The germinal center: A crucible for lymphocyte selection Semin Immunol 1996, 8:179-84 10.1006/smim.1996.0022 8738917
32. Han S Dillon SR Zheng B Shimoda M Schlissel MS Kelsoe G V(D)J recombinase activity in a subset of germinal center B lymphocytes Science 1997, 278:301-5 10.1126/science.278.5336.301 9323211
33. Kim D Wang L Beconi M Eiermann GJ Fisher MH He H Hickey GJ Kowalchick JE Leiting B Lyons K et al (2R)-4-oxo-4-[3-(trifluoromethyl -5,6-dihydro[1,2,4] triazolo[4,3-a]pyrazin -7(8H -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005, 48:141-51 10.1021/jm0493156 15634008
34. Hegen M Mittrucker HW Hug R Demuth HU Neubert K Barth A Fleischer B Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells Immunobiology 1993, 189:483-93 7907318
35. Huhn J Ehrlich S Fleischer B von Bonin A Molecular analysis of CD26-mediated signal transduction in T cells Immunol Lett 2000, 72:127-32 10.1016/S0165-2478(00)00170-X 10841948
36. Tanaka S Murakami T Horikawa H Sugiura M Kawashima K Sugita T Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV Int J Immunopharmacol 1997, 19:15-24 10.1016/S0192-0561(97)00004-0 9226475
37. von Bonin A Huhn J Fleischer B Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway Immunol Rev 1998, 161:43-53 10.1111/j.1600-065X.1998.tb01570.x 9553763
38. Busso N Wagtmann N Herling C Chobaz-Peclat V Bischof-Delaloye A So A Grouzmann E Circulating CD26 is negatively associated with inflammation in human and experimental arthritis Am J Pathol 2005, 166:433-42 1602320 15681827
39. Reinhold D Bank U Buhling F Lendeckel U Faust J Neubert K Ansorge S Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells Immunology 1997, 91:354-60 1364003 9301523 10.1046/j.1365-2567.1997.d01-2258.x
40. Dong RP Tachibana K Hegen M Munakata Y Cho D Schlossman SF Morimoto C Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation J Immunol 1997, 159:6070-6 9550406
41. Ludwig K Fan H Dobers J Berger M Reutter W Bottcher C 3D structure of the CD26-ADA complex obtained by cryo-EM and single particle analysis Biochem Biophys Res Commun 2004, 313:223-9 10.1016/j.bbrc.2003.11.112 14684150
42. Biftu T Scapin G Singh S Feng D Becker JW Eiermann G He H Lyons K Patel S Petrov A et al Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin Bioorg Med Chem Lett 2007, 17:3384-7 10.1016/j.bmcl.2007.03.095 17433672
43. Cordero OJ Yang CP Bell EB On the role of CD26 in CD4 memory T cells Immunobiology 2007, 212:85-94 10.1016/j.imbio.2006.12.002 17336829
44. Ishii T Ohnuma K Murakami A Takasawa N Kobayashi S Dang NH Schlossman SF Morimoto C CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO Proc Natl Acad Sci USA 2001, 98:12138-43 59781 11593028 10.1073/pnas.211439098
45. Boonacker E Van Noorden CJ The multifunctional or moonlighting protein CD26/DPPIV Eur J Cell Biol 2003, 82:53-73 10.1078/0171-9335-00302 12647932
46. Tanaka T Kameoka J Yaron A Schlossman SF Morimoto C The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity Proc Natl Acad Sci USA 1993, 90:4586-90 46557 7685106 10.1073/ pnas.90.10.4586
47. Boonacker EP Wierenga EA Smits HH Van Noorden CJ CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry J Histochem Cytochem 2002, 50:1169-77 12185194
48. Christopherson KW Cooper S Hangoc G Broxmeyer HE CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/ - mice Exp Hematol 2003, 31:1126-34 14585379
49. Oravecz T Pall M Roderiquez G Gorrell MD Ditto M Nguyen NY Boykins R Unsworth E Norcross MA Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage J Exp Med 1997, 186:1865-72 2199148 9382885 10.1084/ jem.186.11.1865
50. Proost P De Meester I Schols D Struyf S Lambeir AM Wuyts A Opdenakker G De Clercq E Scharpe S Van Damme J Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection J Biol Chem 1998, 273:7222-7 10.1074/jbc.273.13.7222 9516414
51. Proost P Schutyser E Menten P Struyf S Wuyts A Opdenakker G Detheux M Parmentier M Durinx C Lambeir AM et al Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties Blood 2001, 98:3554-61 10.1182/blood.V98.13.3554 11739156
52. Shioda T Kato H Ohnishi Y Tashiro K Ikegawa M Nakayama EE Hu H Kato A Sakai Y Liu H et al Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage Proc Natl Acad Sci USA 1998, 95:6331-6 27682 9600965 10.1073/pnas.95.11.6331
53. Struyf S Menten P Lenaerts JP Put W D'Haese A De Clercq E Schols D Proost P Van Damme J Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils Eur J Immunol 2001, 31:2170-8 10.1002/1521-4141(200107)31:7<2170::AID-IMMU2170>3.0.CO;2-D 11449371
54. Struyf S Proost P Schols D De Clercq E Opdenakker G Lenaerts JP Detheux M Parmentier M De Meester I Scharpe S et al CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3 J Immunol 1999, 162:4903-9 10202035
55. Ajami K Pitman MR Wilson CH Park J Menz RI Starr AE Cox JH Abbott CA Overall CM Gorrell MD Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8 FEBS Lett 2008, 582:819-25 10.1016/j.febslet.2008.02.005 18275857